☆ 4.7 Meeting Abstract

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).

JOURNAL OF CLINICAL ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 15, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2021.39.15_suppl.592

Keywords

-

Categories

Oncology

Funding

  1. Genentech
  2. Conquer Cancer Foundation of the American Society of Clinical Oncology
  3. MD Anderson Breast Cancer Moon Shots Program

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.